In addition, high-quality evidence also suggested that for patients with DCM, adding the Qili Qiangxin capsule to conventional Western medicine therapy could significantly improve 6-WMD and reduce IL-6, TNF-α, and HMGB1; adding SMI to conventional treatment could lead to a pronounced improvement in clinical outcomes and decrease in LVESD; in addition, adding Zhigancao to Western treatment could obviously improve LVEF and reduce LVEDD and heart rate; meanwhile, adding Shengmai also had significant advantages in improving the excellence effect. This evidence concerns the gene HMGB1 and familial dilated cardiomyopathy.